outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
Published 2 years ago • 41 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
4:26
outcomes of ird in r/r multiple myeloma in routine clinical practice
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
2:12
using a novel machine learning model to analyze and predict the outcomes of patients with ndmm
-
9:25
mgus diagnosis: a step-by-step approach
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
13:35
2014 agt conference chromothripsis presentation
-
1:06
feasibility of treatment with bispecifics in patients with myeloma with prior bcma exposure
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
2:07
challenges associated with the management of extramedullary myeloma & ongoing research
-
1:00
proof of principle to progress treatments
-
3:24
novel agents for the management of r/r myeloma
-
1:30
the prognostic value of patient-reported outcomes in mds
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing